Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subclinical-dose cyclosporine plus glucocorticoid for moderate to severe bullous pemphigoid
ChiCTR2000029007Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- Jan 2020
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cyclosporine, prednisone, methylprednisolone and halometasone in Bullous Pemphigoid (BP) (2 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: BP180 and BP230. Started Jan 2020; status: recruiting.
02
Drugs
cyclosporineprednisonemethylprednisolonehalometasone
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on ChiCTR2000029007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029007.